No Redo On Asacol Class Decertification At 1st Circ.
The full First Circuit on Wednesday refused to reconsider a panel decision decertifying a class of buyers who allegedly overpaid for Allergan's ulcerative colitis drug Asacol, in what could be another...To view the full article, register now.
Already a subscriber? Click here to view full article